Novo Nordisk’s Zenagamtide Isn’t Chasing Ozempic — It’s Trying to Make Tirzepatide Obsolete

Picture the Novo Nordisk business development team in a conference room at ADA 2026, watching the Phase 2 readout scroll across the screen: 14.6% weight loss at week 36, 89.1% of patients achieving an A1C below 7%, six subcutaneous doses evaluated, once-weekly administration. The data on zenagamtide — also known internally as amycretin — lands with the kind of quiet that precedes a very loud strategic conversation. Someone in that room already has a tirzepatide slide open on their laptop.

Novo Nordisk built a $50 billion commercial franchise on semaglutide — Ozempic in diabetes, Wegovy in obesity — and spent the last three years watching Eli Lilly’s dual GIP/GLP-1 agonist tirzepatide systematically outperform it on weight endpoints. In SURMOUNT-1, tirzepatide delivered between 16.0% and 22.5% weight loss depending on dose, in adults without diabetes. Semaglutide’s STEP 1 trial landed at -14.9% at 68 weeks in a comparable population. The commercial narrative wrote itself: Lilly won the weight war, and Novo was defending market share with volume, pricing, and access rather than efficacy.

Zenagamtide changes that calculation — not incrementally, but architecturally.

A New Receptor, A New Ceiling

What separates zenagamtide from every other asset crowding the GLP-1 space is its mechanism. Every major approved therapy in this class — semaglutide, tirzepatide — works through GLP-1 receptors, with tirzepatide adding GIP as the second target. Zenagamtide pairs GLP-1 with amylin receptors instead. Amylin is a pancreatic hormone that slows gastric emptying and reduces postprandial glucagon secretion, acting on satiety pathways that GIP co-stimulation does not fully address. On paper, this opens a biologically distinct ceiling on weight loss. In practice, 14.6% at week 36 in a type 2 diabetes population — a group that historically underperforms on weight endpoints compared to pure obesity cohorts — suggests that ceiling may be meaningfully higher than semaglutide’s.

The type 2 diabetes population matters commercially, not just scientifically. The global T2D market is projected to reach $64 billion by 2026 across seven major markets, driven precisely by the crossover between glycemic control and weight reduction that payers and prescribers now treat as a bundled requirement. A drug that achieves near-normalization of A1C — 89.1% of patients below 7%, a threshold most endocrinologists consider aggressive — while delivering weight loss that matches or approaches semaglutide’s obesity-indication benchmark is not a diabetes drug with a nice weight-loss side effect. It is a metabolic reset agent with a dual billing address.

And that re-billing matters enormously when you are trying to justify a premium price point to Express Scripts.

Here is the counterintuitive read that most coverage is missing: zenagamtide’s competitive threat is not to Ozempic. Ozempic is already Novo Nordisk’s. The real target is tirzepatide’s expanding moat — specifically Mounjaro’s stronghold in T2D accounts where endocrinologists have already switched patients to the dual GIP/GLP-1 mechanism on the strength of SURPASS trial data. Zenagamtide gives those physicians a reason to switch back, and it gives Novo’s managed care team a scientifically differentiated story rather than a rebate-driven one.

The Competitive Clock Is Running

Novo Nordisk does not have the ADA floor to itself. At the same conference in June 2026, Hengrui Pharma and Kailera Therapeutics presented data on ribupatide — also known as HRS9531 or KAI-9531 — a GLP-1/GIP dual agonist targeting the same metabolic patient population. Eli Lilly’s retatrutide, a GLP-1/GIP/glucagon triple agonist, has Phase 3 data in hand. The mechanism arms race is accelerating: every six months, a new combination therapy arrives with a slightly different receptor profile and a slightly more aggressive weight-loss claim.

In that environment, a Phase 2 readout — even a strong one — is a strategic signal, not a launch. Zenagamtide at 40 mg hit 14.6% at week 36. Week 36 is not week 68, which is the standard endpoint for semaglutide’s obesity trials, and it is not the 72-week window Lilly used in SURMOUNT-1. The honest comparison requires adjusting for both trial duration and patient population — T2D patients lose weight more slowly than non-diabetic obesity patients due to insulin resistance and the glucose-lowering effect of the drug itself consuming some of the metabolic action. When you apply that lens, zenagamtide’s 14.6% at 36 weeks in T2D patients is potentially tracking toward 18–20% in an obesity-only population at 68 weeks. That projection is not a data point — but a Phase 3 design team at Novo Nordisk is almost certainly running that math right now.

The phase 2 study evaluated six subcutaneous doses, which is the kind of dose-ranging breadth you deploy when you are serious about finding the optimal Phase 3 dose before locking in a $400 million confirmatory trial. Novo is not hedging. This is a committed development program.

What Novo Does With This Window

The strategic question is what Novo Nordisk does with the 18-to-24-month window between this Phase 2 readout and a Phase 3 initiation — assuming a mid-2026 start, with data unlikely before 2029 at the earliest in obesity. The company’s playbook from semaglutide’s development suggests aggressive label sequencing: T2D first, obesity second, cardiovascular outcomes third. That sequencing maximizes payer access at launch because T2D has established formulary slots, then converts the weight-loss clinical narrative into an obesity indication that commands premium positioning.

But tirzepatide’s success has complicated that playbook. Mounjaro launched in T2D in 2022 and Zepbound followed in obesity in late 2023 — Lilly moved faster between indications than anyone anticipated, and it created a market structure where physicians now think about GLP-1 class agents as metabolic platforms, not disease-specific drugs. A zenagamtide launch that follows the same sequential logic will face a tirzepatide that has four more years of real-world data, established KOL advocacy, and formulary positions hardened by rebate contracts.

Novo’s only viable counter is differentiation on mechanism, not sequencing. The amylin receptor story gives them that — but only if Phase 3 is designed to prove it. A non-inferiority trial against tirzepatide in T2D weight loss tells the market nothing useful. A superiority trial, powered on the 89.1% A1C responder rate and a weight-loss endpoint that beats tirzepatide head-to-head, tells the market everything. Designing that trial is a $500 million bet on a scientific hypothesis that the amylin-GLP-1 combination opens weight-loss pathways that GIP-GLP-1 cannot reach.

That bet is not unreasonable. It may, in fact, be the only commercial bet worth making in this space in 2026.

Walk back into that ADA conference room. The data is still on the screen. The tirzepatide slide is still open on the laptop. Someone is now calculating not what zenagamtide is worth as a diabetes drug — but what it is worth as the asset that forces Lilly to run a head-to-head it has spent three years avoiding. That is the number that should be on the whiteboard.

References

1. PR Newswire / Novo Nordisk — “Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes — presented at ADA 2026”
2. AJMC — “Trial Finds Semaglutide With Lifestyle Intervention Reduces Body Weight by Nearly 15%” (STEP 1 trial data)
3. PR Newswire / Eli Lilly — “Lilly’s SURMOUNT-1 Results Published in the New England Journal of Medicine Show Tirzepatide Achieved Between 16.0% and 22.5% Weight Loss”
4. Pharmacy Times — “Type 2 Diabetes Market to Reach $64 Billion by 2026”
5. GlobeNewswire / Hengrui Pharma & Kailera Therapeutics — “Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026”